Published in Radiat Oncol on June 26, 2014
Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer (2016) 2.02
Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol (2016) 0.79
Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. Front Oncol (2016) 0.76
CyberKnife-based prostate cancer patient radioablation - early results of irradiation in 200 patients. Cent European J Urol (2015) 0.75
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care (1996) 70.87
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care (2003) 19.69
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol (1992) 13.63
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 6.42
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol (2011) 2.57
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol (2009) 2.33
Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 2.26
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol (2005) 2.18
Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 2.16
Analysis of continence rates following robot-assisted radical prostatectomy: strict leak-free and pad-free continence. Urology (2009) 2.16
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 2.15
Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer (2007) 2.13
The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol (2013) 2.10
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer (2011) 1.98
Correlates of bother following treatment for clinically localized prostate cancer. J Urol (2010) 1.82
Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int (2006) 1.79
Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 1.77
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.75
Variation in continence and potency by definition. J Urol (2003) 1.75
Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.73
Post-prostatectomy urinary incontinence: a confluence of 3 factors. J Urol (2010) 1.64
Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr (2012) 1.49
The prevalence of urinary incontinence among community dwelling men: results from the National Health and Nutrition Examination survey. J Urol (2006) 1.36
The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care (2005) 1.34
Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer (2013) 1.31
Care seeking and treatment for urinary incontinence in a diverse population. J Urol (2007) 1.28
Urologic diseases in America project: urinary incontinence in males--demographics and economic burden. J Urol (2005) 1.22
Hypofractionation for prostate cancer. Cancer J (2009) 1.21
External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys (2010) 1.21
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. Radiat Oncol (2012) 1.21
Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys (2008) 1.19
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys (2007) 1.17
Continence following radical retropubic prostatectomy using self-reporting instruments. J Urol (2004) 1.09
Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. Urology (2006) 1.08
Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol (2013) 1.07
Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. J Urol (2001) 1.06
Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer (2012) 1.04
Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy. Front Oncol (2011) 1.04
Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol (2009) 0.99
Pad use and patient reported bother from urinary leakage after radical prostatectomy. J Urol (2011) 0.92
Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys (1999) 0.90
Urinary incontinence following treatment of localized prostate cancer. Cancer Control (2002) 0.90
Urinary incontinence. Prim Care (2010) 0.88
Stratification of postprostatectomy urinary function using expanded prostate cancer index composite. Urology (2012) 0.84
Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy. Br J Cancer (2013) 0.82
Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol (2014) 0.78
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol (2011) 4.59
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol (2009) 2.81
Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg (2006) 2.52
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 2.16
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med (2012) 2.08
MYB gene abnormalities t(6;9) in adenoid cystic carcinoma fine-needle aspiration biopsy using fluorescence in situ hybridization. Arch Pathol Lab Med (2014) 2.03
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care (2007) 1.70
The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 1.70
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis (2011) 1.70
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol (2011) 1.58
Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2006) 1.49
Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging (2008) 1.48
The impact of radiosurgery fractionation and tumor radiobiology on the local control of brain metastases. J Neurosurg (2013) 1.48
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
Site-specific incorporation of keto amino acids into functional G protein-coupled receptors using unnatural amino acid mutagenesis. J Biol Chem (2007) 1.45
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
On the equivalence of some medical cost estimators with censored data. Stat Med (2007) 1.43
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Reproducibility and reliability of atherosclerotic plaque volume measurements in peripheral arterial disease with cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2007) 1.40
Cholangiocarcinoma in a 17-year-old boy with primary sclerosing cholangitis and UroVysion™ fluorescent in situ hybridization. Diagn Cytopathol (2011) 1.40
Transcriptional repression by binding of poly(ADP-ribose) polymerase to promoter sequences. J Biol Chem (2001) 1.37
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res (2004) 1.26
Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem (2012) 1.25
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A (2013) 1.20
MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One (2013) 1.19
Complications of thoracic computed tomography-guided fiducial placement for the purpose of stereotactic body radiation therapy. Clin Lung Cancer (2007) 1.19
Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol (2009) 1.18
Tamoxifen-induced radiation recall dermatitis. Breast J (2004) 1.18
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol (2013) 1.18
Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res (2007) 1.13
Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol (2009) 1.13
CyberKnife radiosurgery in the treatment of complex skull base tumors: analysis of treatment planning parameters. Radiat Oncol (2006) 1.11
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett (2005) 1.10
CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung Cancer. Front Oncol (2012) 1.09
CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol (2010) 1.08
A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer. Technol Cancer Res Treat (2010) 1.07
ATM missense mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet (2003) 1.06
Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy. Front Oncol (2011) 1.04
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol (2013) 1.04
Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res (2006) 1.02
Obesity does not increase complications after anatomic resection for non-small cell lung cancer. Ann Thorac Surg (2007) 0.99
The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol (2004) 0.99
Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids (2008) 0.98
Integrated analysis of ATM mediated gene and protein expression impacting cellular metabolism. J Proteome Res (2011) 0.97
DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci U S A (2013) 0.96
βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology (2015) 0.95
Rapid on-site evaluation for endoscopic ultrasound-guided fine-needle biopsy of the pancreas decreases the incidence of repeat biopsy procedures. Cancer Cytopathol (2013) 0.95
Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis. Cancer (2007) 0.95
DNA transitions induced by binding of PARP-1 to cruciform structures in supercoiled plasmids. Cytometry A (2005) 0.94
Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol (2011) 0.94
Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res (2002) 0.94
Omics-based molecular target and biomarker identification. Methods Mol Biol (2011) 0.93
BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem (2004) 0.93
The prevalence of extracardiac findings by multidetector computed tomography before atrial fibrillation ablation. Am Heart J (2007) 0.92
Statin therapy improves outcomes after valvular heart surgery. Ann Thorac Surg (2008) 0.92
Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet (2002) 0.92
Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells. J Nutr Biochem (2011) 0.91
CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol (2010) 0.91